In Silico Coformer Screening for Mefenamic Acid Cocrystallization

Aulia Fikri Hidayat; Taufik Muhammad Fakih; Gita Cahya Eka Darma; Ratu Choesrina

doi:10.31965/infokes.Vol22.Iss1.1375

Authors

Aulia Fikri Hidayat Department of Pharmacy, Bandung Islamic University, Bandung, West Java, Indonesia
Taufik Muhammad Fakih Department of Pharmacy, Bandung Islamic University, Bandung, West Java, Indonesia
Gita Cahya Eka Darma Department of Pharmacy, Bandung Islamic University, Bandung, West Java, Indonesia
Ratu Choesrina Department of Pharmacy, Bandung Islamic University, Bandung, West Java, Indonesia

DOI:

https://doi.org/10.31965/infokes.Vol22.Iss1.1375

Keywords:

Cocrystal, Coformer, Screening, Molecular Docking, Mefenamic Acid

Abstract

Cocrystallization is a widely used approach to enhance the solubility and dissolution characteristics of poorly soluble drugs. A pharmaceutical cocrystal is a multicomponent system composed of a solid active pharmaceutical ingredient (API) and a coformer, governed by non-covalent interactions. Screening for suitable coformers is essential to obtain an optimal cocrystal for specific drugs. This study aims to determine the drug-coformer interactions to select the most suitable coformer for cocrystal formation using the molecular docking method. Mefenamic acid, classified as a class II drug in the biopharmaceutical classification system (BCS), was used as the model drug. Two-dimensional structures of mefenamic acid (PubChem CID: 4044) and potential coformers were sourced from PubChem. Geometric optimization of all compounds was performed using GaussView 5.0.8 and Gaussian09 with the 3-21G basis set and Density Functional Theory (DFT) B3LYP method. The optimized compounds were prepared by adding hydrogen atoms and calculating Kollman partial charges using AutoDock 4.2. A grid box of size 40 Å × 40 Å × 40 Å was generated, with a maximum radius of 0.375 Å set as the surface distance in each simulation. A hundred conformations were run using the Lamarckian Genetic Algorithm. Interaction types and binding energies were analyzed using VMD 1.9.2 and BIOVIA Discovery Studio 2020 to compare interactions between mefenamic acid and each coformer. The results revealed that most coformer compounds formed interactions with mefenamic acid via hydrogen bonding and π–interactions. Saccharin demonstrated the most optimal interaction with mefenamic acid, with a binding free energy of –3.1 kcal/mol. Saccharin was identified as the most suitable coformer for mefenamic acid cocrystal formation based on the molecular docking study. Further experimental validation of saccharin is recommended to confirm its effectiveness in cocrystallization with mefenamic acid.

Downloads

Download data is not yet available.

References

Berry, D. J., & Steed, J. W. (2017). Pharmaceutical cocrystals, salts and multicomponent systems; intermolecular interactions and property based design. In Advanced Drug Delivery Reviews (Vol. 117, pp. 3–24). Elsevier B.V. https://doi.org/10.1016/j.addr.2017.03.003

Bhandaru, J. S., Malothu, N., & Akkinepally, R. R. (2015). Characterization and solubility studies of pharmaceutical cocrystals of eprosartan mesylate. Crystal Growth and Design, 15(3), 1173–1179. https://doi.org/10.1021/cg501532k

Bora, P., Saikia, B., & Sarma, B. (2018). Regulation of π···π Stacking Interactions in Small Molecule Cocrystals and/or Salts for Physiochemical Property Modulation. Crystal Growth and Design, 18(3), 1448–1458. https://doi.org/10.1021/acs.cgd.7b01377

Censi, R., & Di Martino, P. (2015). Polymorph impact on the bioavailability and stability of poorly soluble drugs. Molecules, 20(10), 18759–18776. https://doi.org/10.3390/molecules201018759

Cimolai, N. (2013). The potential and promise of mefenamic acid. In Expert Review of Clinical Pharmacology (Vol. 6, Issue 3, pp. 289–305). https://doi.org/10.1586/ecp.13.15

Gajjar, A., Savjani, J. K., Pathak, C. D., Savjani, K. T., Gajjar, A. K., & Savjani, J. K. (2013). Cocrystal formation of paracetamol with indomethacin and mefenamic acid: An efficient approach to enhance solubility. International Journal of Pharmacy and Pharmaceutical Sciences.

Grimme, S. (2008). Do special noncovalent π-π stacking interactions really exist? Angewandte Chemie - International Edition, 47(18), 3430–3434. https://doi.org/10.1002/anie.200705157

Karimi-Jafari, M., Padrela, L., Walker, G. M., & Croker, D. M. (2018). Creating cocrystals: A review of pharmaceutical cocrystal preparation routes and applications. In Crystal Growth and Design (Vol. 18, Issue 10, pp. 6370–6387). American Chemical Society. https://doi.org/10.1021/acs.cgd.8b00933

Khalaji, M., Potrzebowski, M. J., & Dudek, M. K. (2021). Virtual Cocrystal Screening Methods as Tools to Understand the Formation of Pharmaceutical Cocrystals - A Case Study of Linezolid, a Wide-Range Antibacterial Drug. Crystal Growth and Design, 21(4), 2301–2314. https://doi.org/10.1021/acs.cgd.0c01707

Kumar, A., & Nanda, A. (2021). In-silico methods of cocrystal screening: A review on tools for rational design of pharmaceutical cocrystals. In Journal of Drug Delivery Science and Technology (Vol. 63). Editions de Sante. https://doi.org/10.1016/j.jddst.2021.102527

Li, D., Kong, M., Li, J., Deng, Z., & Zhang, H. (2018). Amine-carboxylate supramolecular synthon in pharmaceutical cocrystals. CrystEngComm, 20(35), 5112–5118. https://doi.org/10.1039/C8CE01106K

Liu, Y., Li, S., Xu, J., Zhang, H., Guan, Y., Jiang, H., Huang, S., Huang, H., & Wang, Z. (2018). Three Energetic 2,2′,4,4′,6,6′-Hexanitrostilbene Cocrystals Regularly Constructed by H-bonding, π-Stacking, and van der Waals Interactions. Crystal Growth and Design, 18(4), 1940–1943. https://doi.org/10.1021/acs.cgd.8b00019

Mangesh, B., Sumedh, P., Sumedh, M., & Pradhan, B. (2019). Scientific Coformer Screening, Preparation and Evaluation of Fenofibrate Tartaric Acid Cocrystal. Journal of Drug Delivery and Therapeutics, 9(4), 406–410. https://doi.org/10.22270/jddt.v9i4.3199

Mohammad, M. A., Alhalaweh, A., & Velaga, S. P. (2011). Hansen solubility parameter as a tool to predict cocrystal formation. International Journal of Pharmaceutics, 407(1–2), 63–71. https://doi.org/10.1016/j.ijpharm.2011.01.030

Musumeci, D., Hunter, C. A., Prohens, R., Scuderi, S., & McCabe, J. F. (2011). Virtual cocrystal screening. Chemical Science, 2(5), 883–890. https://doi.org/10.1039/c0sc00555j

Nurhikmah, W., Sumirtapura, Y. C., & Pamudji, J. S. (2016). Dissolution profile of mefenamic acid solid dosage forms in two compendial and biorelevant (FaSSIF) media. Scientia Pharmaceutica, 84(1), 181–190. https://doi.org/10.3797/scipharm.ISP.2015.09

Putra, O. D., Umeda, D., Fujita, E., Haraguchi, T., Uchida, T., Yonemochi, E., & Uekusa, H. (2018). Solubility improvement of benexate through salt formation using artificial sweetener. Pharmaceutics, 10(2). https://doi.org/10.3390/pharmaceutics10020064

Saha, S., & Desiraju, G. R. (2018). Acid⋯Amide Supramolecular Synthon in Cocrystals: From Spectroscopic Detection to Property Engineering. Journal of the American Chemical Society, 140(20), 6361–6373. https://doi.org/10.1021/jacs.8b02435

Sarcevica, I., Orola, L., Belyakov, S., & Veidis, M. V. (2013). Spontaneous cocrystal hydrate formation in the solid state: Crystal structure aspects and kinetics. New Journal of Chemistry, 37(10), 2978–2982. https://doi.org/10.1039/c3nj00489a

Singh, M., Barua, H., Jyothi, V. G. S. S., Dhondale, M. R., Nambiar, A. G., Agrawal, A. K., Kumar, P., Shastri, N. R., & Kumar, D. (2023). Cocrystals by Design: A Rational Coformer Selection Approach for Tackling the API Problems. In Pharmaceutics (Vol. 15, Issue 4). MDPI. https://doi.org/10.3390/pharmaceutics15041161

Siswandi, S., Rusdiana, T., & Levita, J. (2015). Virtual screening of co-formers for ketoprofen co-crystallization and the molecular properties of the co-crystal. Journal of Applied Pharmaceutical Science, 5(6), 078–082. https://doi.org/10.7324/JAPS.2015.50613

Tahir, M. N., Ashfaq, M., de la Torre, A. F., Caballero, J., Hernández-Rodríguez, E. W., & Ali, A. (2019). Rationalizing the stability and interactions of 2,4-diamino-5-(4-chlorophenyl)-6-ethylpyrimidin-1-ium 2-hydroxy-3,5-dinitrobenzoate salt. Journal of Molecular Structure, 1193, 185–194. https://doi.org/10.1016/j.molstruc.2019.05.003

Taylor, C. R., & Day, G. M. (2018). Evaluating the Energetic Driving Force for Cocrystal Formation. Crystal Growth and Design, 18(2), 892–904. https://doi.org/10.1021/acs.cgd.7b01375

Utami, D. W. I., Nugrahani, I., & Ibrahim, S. (2017). Mefenamic acid-nicotinamide co-crystal synthesized by using melt crystallization method and its solubility study. Asian Journal of Pharmaceutical and Clinical Research, 10(5), 135–139. https://doi.org/10.22159/ajpcr.2017.v10i5.15863

Vener, M. V., Levina, E. O., Koloskov, O. A., Rykounov, A. A., Voronin, A. P., & Tsirelson, V. G. (2014). Evaluation of the lattice energy of the two-component molecular crystals using solid-state density functional theory. Crystal Growth and Design, 14(10), 4997–5003. https://doi.org/10.1021/cg5005243

Wouters, J., Rome, S., & Quéré, L. (2011). Monographs of most Frequent Co-Crystal Formers. In J. Wouters & L. Quéré (Eds.), Pharmaceutical Salts and Co-crystals (p. 0). The Royal Society of Chemistry. https://doi.org/10.1039/9781849733502-00338

Zhang, H., Sun, S., Wang, Y., & Cao, J. (2017). Interaction of sucralose with whey protein: Experimental and molecular modeling studies. Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 187, 92–97. https://doi.org/10.1016/j.saa.2017.06.030